Stock Analysis

3 KRX Growth Companies With Up To 26% Insider Ownership

The South Korea stock market has moved higher in five straight sessions, improving almost 90 points or 3.4 percent along the way. The KOSPI now sits just above the 2,600-point plateau and it may tick higher again on Tuesday amid positive momentum and a lack of catalysts. In such a promising market environment, identifying growth companies with high insider ownership can be particularly advantageous as it often indicates strong confidence from those closest to the business.

Top 10 Growth Companies With High Insider Ownership In South Korea

NameInsider OwnershipEarnings Growth
People & Technology (KOSDAQ:A137400)16.4%35.6%
Seojin SystemLtd (KOSDAQ:A178320)30.5%52.1%
Bioneer (KOSDAQ:A064550)15.8%97.6%
Oscotec (KOSDAQ:A039200)26.3%122%
ALTEOGEN (KOSDAQ:A196170)26.6%99.5%
Park Systems (KOSDAQ:A140860)33%35.7%
Vuno (KOSDAQ:A338220)19.5%110.9%
HANA Micron (KOSDAQ:A067310)18.3%100.3%
UTI (KOSDAQ:A179900)33.1%134.6%
Techwing (KOSDAQ:A089030)18.7%83.6%

Click here to see the full list of 88 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

S&S Tech (KOSDAQ:A101490)

Simply Wall St Growth Rating: ★★★★★☆

Overview: S&S Tech Corporation manufactures and sells blank masks worldwide, with a market cap of ₩524.71 billion.

Operations: S&S Tech Corporation generates revenue primarily from the sale of blank masks globally.

Insider Ownership: 22.6%

S&S Tech, a growth company with high insider ownership in South Korea, is forecasted to achieve significant earnings growth at 36.8% annually over the next three years, outpacing the market's 29%. Recent earnings reports show a net income increase to ₩7.91 billion for Q2 2024 from ₩5.78 billion a year ago. Additionally, S&S Tech announced a share repurchase program worth ₩10 billion to enhance shareholder value and stabilize its stock price by November 2024.

KOSDAQ:A101490 Ownership Breakdown as at Sep 2024

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩18.59 billion.

Operations: Revenue from biotechnology amounts to ₩90.79 million.

Insider Ownership: 26.6%

ALTEOGEN, with high insider ownership, is transitioning to a commercial-stage company following the MFDS approval of Tergase®, its recombinant hyaluronidase. This milestone product boasts over 99% purity and lower immunogenicity compared to animal-derived alternatives. Forecasts indicate ALTEOGEN's revenue will grow at 64.2% annually, significantly outpacing the market average. Despite past shareholder dilution, earnings are expected to increase by 99.46% per year, with profitability anticipated within three years and a very high forecasted return on equity of 66.3%.

KOSDAQ:A196170 Earnings and Revenue Growth as at Sep 2024

Lunit (KOSDAQ:A328130)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Lunit Inc. develops and provides AI-based software solutions for cancer screening, diagnosis, and treatment, with a market cap of ₩1.26 trillion.

Operations: Lunit's revenue from healthcare software solutions amounts to ₩26.03 billion.

Insider Ownership: 21%

Lunit, a growth company with high insider ownership, recently announced its AI-powered chest X-ray analysis software, Lunit INSIGHT CXR, achieved the highest AUC of 0.902 in a large-scale TB detection study published in The Lancet Digital Health. This robust performance underscores its potential for improving TB screening efficiency. Additionally, Teri Thomas was appointed as Chief Business Officer to expand Lunit's market presence in the US and EMEA regions. Earnings are forecast to grow 104.93% annually with profitability expected within three years.

KOSDAQ:A328130 Ownership Breakdown as at Sep 2024

Summing It All Up

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com